{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T19:12:46Z","timestamp":1787339566827,"version":"build-2736575974"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04046\/2020"],"award-info":[{"award-number":["UIDP\/04046\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04046\/2020"],"award-info":[{"award-number":["UIDB\/04046\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["H2020-SC1-2017-755021"],"award-info":[{"award-number":["H2020-SC1-2017-755021"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SRC-2024-026"],"award-info":[{"award-number":["SRC-2024-026"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.09.013","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T16:38:15Z","timestamp":1727282295000},"page":"10-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Theranostics vs theratyping or theranostics plus theratyping?"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida D.","family":"Amaral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Pankonien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.09.013_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031437","article-title":"Assays of CFTR Function In Vitro, Ex Vivo and In Vivo","volume":"23","author":"Ramalho","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.09.013_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: from molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2015","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jcf.2024.09.013_bib0004","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"De Boeck","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0005","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.e14-04-0935","article-title":"From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations","volume":"27","author":"Veit","year":"2016","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jcf.2024.09.013_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2004.05.040","article-title":"Established cell lines used in cystic fibrosis research","volume":"3","author":"Gruenert","year":"2004","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0007","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00404.2009","article-title":"Influence of cell background on pharmacological rescue of mutant CFTR","volume":"298","author":"Pedemonte","year":"2010","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2024.09.013_bib0008","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00507.2010","article-title":"Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling","volume":"301","author":"Sondo","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jcf.2024.09.013_bib0009","doi-asserted-by":"crossref","DOI":"10.2174\/13816128113199990318","article-title":"Rescuing Mutant CFTR: a Multi-task Approach to a Better Outcome in Treating Cystic Fibrosis","volume":"19","author":"D. Amaral","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jcf.2024.09.013_bib0010","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-61779-117-8_4","article-title":"Use of Primary Cultures of Human Bronchial Epithelial Cells Isolated from Cystic Fibrosis Patients for the Pre-clinical Testing of CFTR Modulators","volume":"741","author":"Neuberger","year":"2011","journal-title":"Methods Molecular Biology"},{"key":"10.1016\/j.jcf.2024.09.013_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2020.12.019","article-title":"Significant functional differences in differentiated Conditionally Reprogrammed (CRC)- and Feeder-free Dual SMAD inhibited-expanded human nasal epithelial cells","volume":"20","author":"Awatade","year":"2021","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0012","article-title":"Choice of Differentiation Media Significantly Impacts Cell Lineage and Response to CFTR Modulators in Fully Differentiated Primary Cultures of Cystic Fibrosis Human Airway Epithelial Cells","volume":"9","author":"Saint-Criq","year":"2020","journal-title":"CellsCells"},{"key":"10.1016\/j.jcf.2024.09.013_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021246","article-title":"Phenotypic Alteration of an Established Human Airway Cell Line by Media Selection","volume":"24","author":"Livnat","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.09.013_bib0014","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Van Goor","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.013_bib0015","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jcf.2015.11.010","article-title":"Creation and characterization of an airway epithelial cell line for stable expression of CFTR variants","volume":"15","author":"Gottschalk","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.09.013_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","author":"Bihler","year":"2024","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1113\/expphysiol.2011.060756","article-title":"Endogenous surface expression of \u0394F508-CFTR mediates cAMP-stimulated Cl- current inCFTR\u0394F508\/\u0394F508 pig thyroid epithelial cells","volume":"97","author":"Li","year":"2012","journal-title":"Exp Physiol"},{"key":"10.1016\/j.jcf.2024.09.013_bib0018","unstructured":"Vertex Pharmaceuticals Incorporated. https:\/\/cdn.clinicaltrials.gov\/large-docs\/34\/NCT02392234\/Prot_000.pdf n.d."},{"key":"10.1016\/j.jcf.2024.09.013_bib0019","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"21","key":"10.1016\/j.jcf.2024.09.013_bib71","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2024.09.013_bib72","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.jcf.2024.09.013_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1155705","article-title":"Personalized medicine: function of CFTR variant p.Arg334Trp is rescued by currently available CFTR modulators","volume":"10","author":"Railean","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jcf.2024.09.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcf.2024.09.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0024","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jcf.2024.09.013_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2011.12.005","article-title":"Ivacaftor potentiation of multiple CFTR channels with gating mutations","volume":"11","author":"Yu","year":"2012","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0027","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12927","article-title":"G970R-CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect","volume":"14","author":"Fidler","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jcf.2024.09.013_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2017.08.026","article-title":"Ivacaftor for the p.Ser549Arg (S549R) gating mutation \u2013 The Israeli experience","volume":"131","author":"Dagan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0029","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"European Respiratory Journal"},{"key":"10.1016\/j.jcf.2024.09.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2015.11.002","article-title":"Bronchial epithelial cell lines and primary nasal epithelial cells from cystic fibrosis respond differently to cigarette smoke exposure","volume":"15","author":"Williams","year":"2016","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0031","doi-asserted-by":"crossref","DOI":"10.1113\/JP282586","article-title":"Nasal epithelial cells as a gold-standard predictive model for personalized medicine in cystic fibrosis","volume":"600","author":"Pedemonte","year":"2022","journal-title":"Journal of Physiology"},{"key":"10.1016\/j.jcf.2024.09.013_bib0032","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02735-2021","article-title":"Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment","volume":"58","author":"Reeves","year":"2021","journal-title":"European Respiratory Journal"},{"key":"10.1016\/j.jcf.2024.09.013_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2019.05.029","article-title":"Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids","volume":"24","author":"Chen","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jcf.2024.09.013_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2019.11.002","article-title":"Intestinal organoids for Cystic Fibrosis research","author":"de Poel","year":"2020","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2017.10.017","article-title":"Translational research to enable personalized treatment of cystic fibrosis","volume":"17","author":"Hagemeijer","year":"2018","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0036","article-title":"Intestinal organoids and personalized medicine in cystic fibrosis: a successful patient-oriented research collaboration","volume":"22","author":"Noordhoek","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0037","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-016-2258-2","article-title":"The third dimension: new developments in cell culture models for colorectal research","volume":"73","author":"Pereira","year":"2016","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.jcf.2024.09.013_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.11.007","article-title":"Patient-derived cell models for personalized medicine approaches in cystic fibrosis","volume":"22","author":"Ramalho","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2017.09.005","article-title":"Recent progress in translational cystic fibrosis research using precision medicine strategies","volume":"17","author":"Cholon","year":"2018","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101419","article-title":"Isolation, cultivation, and application of primary respiratory epithelial cells obtained by nasal brushing, polyp samples, or lung explants","volume":"3","author":"Golec","year":"2022","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jcf.2024.09.013_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100019","article-title":"Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids","volume":"1","author":"Vonk","year":"2020","journal-title":"STAR Protoc"},{"key":"10.1016\/j.jcf.2024.09.013_bib0042","article-title":"Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe Organoid Study","volume":"0","author":"Bierlaagh","year":"2024","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076576","article-title":"Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators","volume":"24","author":"Terlizzi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.09.013_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.jcf.2024.09.013_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2019.10.022","article-title":"Forskolin-induced swelling of intestinal organoids correlates with disease severity in adults with cystic fibrosis and homozygous F508del mutations","volume":"19","author":"de Winter \u2013 de Groot","year":"2020","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0046","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0047","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"European Respiratory Journal"},{"key":"10.1016\/j.jcf.2024.09.013_bib0048","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-07504-1","article-title":"Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators","volume":"7","author":"Pranke","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcf.2024.09.013_bib0049","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02457-2017","article-title":"Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis","volume":"51","author":"McCarthy","year":"2018","journal-title":"European Respiratory Journal"},{"key":"10.1016\/j.jcf.2024.09.013_bib0050","doi-asserted-by":"crossref","DOI":"10.1513\/AnnalsATS.202001-082RL","article-title":"Correlation between ivacaftor-induced CFTR activation in airway epithelial cells and improved lung function: a proof-of-concept study","volume":"17","author":"Debley","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2024.09.013_bib0051","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.23659","article-title":"In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: n-of-1 studies","volume":"52","author":"McGarry","year":"2017","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.09.013_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.008","article-title":"Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation","author":"Aluma","year":"2024","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914539","article-title":"CFTR Function Restoration upon Elexacaftor\/Tezacaftor\/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare CFTR Genotypes","volume":"24","author":"Lefferts","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.09.013_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","volume":"22","author":"Sadras","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11121376","article-title":"Prediction of real-world long-term outcomes of people with CF homozygous for the F508del mutation treated with CFTR modulators","volume":"11","author":"Muilwijk","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0056","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512365","article-title":"Personalized CFTR Modulator Therapy for G85E and N1303K Homozygous Patients with Cystic Fibrosis","volume":"24","author":"Graeber","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jcf.2024.09.013_bib0057","doi-asserted-by":"crossref","DOI":"10.1113\/JP282143","article-title":"Correlating genotype with phenotype using CFTR-mediated whole-cell Cl\u2212 currents in human nasal epithelial cells","volume":"600","author":"Noel","year":"2022","journal-title":"J Physiology"},{"key":"10.1016\/j.jcf.2024.09.013_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.03.004","article-title":"FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes","volume":"22","author":"de Poel","year":"2023","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0059","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00495-2022","article-title":"High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing","volume":"9","author":"Spelier","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jcf.2024.09.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2017.04.009","article-title":"Biobanking: towards increased access of biomaterials in cystic fibrosis. Report on the pre-conference meeting to the 13th ECFS Basic Science Conference, Pisa, 30 March-2 April 2016","volume":"16","author":"Beekman","year":"2017","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2020.11.015","article-title":"Organoids for personalized treatment of Cystic Fibrosis: professional perspectives on the ethics and governance of organoid biobanking","volume":"20","author":"Lensink","year":"2021","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0062","article-title":"Primary Human Nasal Epithelial Cells: biobanking in the Context of Precision Medicine","volume":"2022","author":"Kelly","year":"2022","journal-title":"J Visualized Experiments"},{"key":"10.1016\/j.jcf.2024.09.013_bib0063","article-title":"Repeatability and reproducibility of the Forskolin-induced swelling (FIS) assay on intestinal organoids from people with Cystic Fibrosis","volume":"0","author":"Bierlaagh","year":"2024","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2021.08.005","article-title":"Promises and challenges of organoid-guided precision medicine","volume":"2","author":"Bose","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.jcf.2024.09.013_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2020.05.012","article-title":"Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders\u2019 consensus view","volume":"19","author":"De Boeck","year":"2020","journal-title":"J Cystic Fibrosis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0066","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06468527 n.d."},{"key":"10.1016\/j.jcf.2024.09.013_bib0067","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"European Respiratory Journal"},{"key":"10.1016\/j.jcf.2024.09.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1165\/rcmb.2023-0398OC","article-title":"Investigation of CFTR Function in Human Nasal Epithelial Cells Informs Personalized Medicine","author":"Pion","year":"2024","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jcf.2024.09.013_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165905","article-title":"Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: the case of S955P and 1717-2A>G","volume":"1866","author":"Silva","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jcf.2024.09.013_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.01.008","article-title":"Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype","volume":"21","author":"Aalbers","year":"2022","journal-title":"J Cystic Fibrosis"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932401782X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156919932401782X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:15:07Z","timestamp":1778620507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156919932401782X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S156919932401782X"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.013","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Theranostics vs theratyping or theranostics plus theratyping?","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}